LLY241220P940000
- 157.00
- 0.000.00%
Eli Lilly and Co Newsroom
Eli Lilly Secures Chinese Approval for Early Symptomatic Alzheimer's Disease Medicine
Eli Lilly's Kisunla Approved for Early Alzheimer's Patients in China
Eli Lilly and Co's potential blockbuster new drug donanemab has been approved for sale in China! It is used for treating Alzheimer's disease.
On December 18, Eli Lilly and Co (LLY.US) just announced that its Class 1 new drug donanemab injection application has been approved by the National Medical Products Administration of China (NMPA).
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Peering Into Eli Lilly's Recent Short Interest
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
NVS Vs. LLY: Which Stock Should Value Investors Buy Now?
Behind the Scenes of Eli Lilly's Latest Options Trends
The Stock Market Is One Big Contradiction Right -2-
Lilly Endowment Donates $10 Million for American Red Cross Service to the Armed Forces
Lilly's Kisunla (Donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Lilly and EVA Pharma Announce Regulatory Approval and Release of Locally Manufactured Insulin in Egypt
Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com
Moderna Remains the Most Shorted Among S&P 500 Healthcare Stocks in November
Express News | Trump: Does Not Like Mandates for Vaccines, When Asked Whether Schools Should Mandate
Another Week, Another Index Record | Lkive Stock
Why the Investor Craze for Ozempic and Rival Weight-loss Drugs May Resume Next Year
The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect